Manta Ray Cartilage (Manta birostris)

Manta ray cartilage (Manta birostris) is a marine-derived tissue theorized to contain antiangiogenic glycoproteins and proteoglycans, compounds that may inhibit new blood vessel formation by interfering with vascular endothelial growth factor (VEGF) signaling. Evidence for any human health benefit remains absent, with no clinical trials specifically evaluating manta ray cartilage as a therapeutic or supplemental agent.

Origin & History

Manta ray cartilage is derived from the skeletal cartilage of the giant oceanic manta ray (Manta birostris), a filter-feeding marine elasmobranch found in tropical and subtropical waters. While extraction methods for manta ray cartilage are not documented, related cartilage from sharks is typically processed into powder or liquid extracts via grinding, enzymatic digestion, or purification. Note that Manta birostris is vulnerable to overexploitation, raising sustainability concerns.

Historical & Cultural Context

No evidence of historical or traditional medicinal use of manta ray cartilage was found in any traditional medicine systems. Modern interest in cartilage supplements stems from 1990s theories about shark cartilage's purported anticancer effects via angiogenesis inhibition, but this is not traditional use and does not apply to manta rays.

Health Benefits

• No documented health benefits - No human clinical trials exist for manta ray cartilage
• Potential antiangiogenic effects - Related liquid cartilage extracts showed reduced wound vascularization in 40 healthy men (evidence: preliminary, not manta-specific)
• No cancer benefits demonstrated - Similar shark cartilage showed no effect on survival or quality of life in 83 advanced cancer patients (PMID: 15912493)
• Unknown bioavailability - While related liquid cartilage showed oral absorption, no data exists for manta ray cartilage specifically
• No traditional medicinal use documented - Unlike other animal cartilages, no historical therapeutic applications found

How It Works

Cartilage-derived tissues from elasmobranch species theoretically contain antiangiogenic proteins such as troponin I homologs and chondroitin sulfate proteoglycans that may downregulate VEGF receptor-2 (KDR/Flk-1) signaling, potentially suppressing endothelial cell proliferation. Chondroitin sulfate side chains on aggrecan and versican may competitively bind angiogenic growth factors, reducing their bioavailability at target tissues. These proposed mechanisms are extrapolated from generic cartilage research and shark cartilage studies and have not been validated using manta ray cartilage specifically in any controlled experimental model.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on manta ray cartilage (Manta birostris) were identified. A related shark cartilage RCT (PMID: 15912493) in 83 cancer patients found no survival benefit at 1 g/kg/day, while another trial (PMID: 10527711) on liquid cartilage extract showed antiangiogenic effects but was not disease-specific and not confirmed as manta-derived.

Clinical Summary

No human clinical trials have been conducted using manta ray cartilage specifically as a supplement or therapeutic agent. A single preliminary study involving liquid cartilage extracts (not confirmed to be manta-derived) observed reduced wound vascularization in 40 healthy male subjects, representing very low-quality, non-specific evidence. The broader shark and ray cartilage literature, including a Phase III randomized controlled trial of shark cartilage (AE-941/Neovastat) in 384 non-small-cell lung cancer patients, found no survival benefit over placebo, casting serious doubt on the antiangiogenic cancer theory for cartilage-based marine supplements. Current evidence is insufficient to support any therapeutic claim for manta ray cartilage in humans.

Nutritional Profile

{"protein": {"content": "High", "bioavailability": "Moderate"}, "minerals": {"calcium": {"content": "High", "bioavailability": "Moderate"}, "phosphorus": {"content": "Moderate", "bioavailability": "Moderate"}, "magnesium": {"content": "Low", "bioavailability": "Low"}}, "bioactive_compounds": {"chondroitin sulfate": {"content": "Moderate", "bioavailability": "Low"}, "glucosamine": {"content": "Low", "bioavailability": "Low"}}}

Preparation & Dosage

No clinically studied dosage ranges exist for manta ray cartilage in any form (extract, powder, or standardized). For context only, unrelated shark cartilage was studied at 1 g/kg/day without standardization specified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

None identified - no synergistic ingredients documented

Safety & Interactions

No formal safety profile or toxicology data exists specifically for manta ray cartilage supplements, making adverse effect prediction difficult. General marine cartilage supplements have been associated with nausea, gastrointestinal discomfort, and hypersensitivity reactions in individuals with shellfish or fish allergies due to shared glycosaminoglycan and protein antigens. Potential interactions with anticoagulant medications such as warfarin are theoretically possible given that chondroitin sulfate components may have mild antiplatelet activity, though this has not been studied for manta ray cartilage. Pregnant and breastfeeding women should avoid this supplement entirely given the complete absence of safety data, and manta birostris is a protected species under CITES Appendix II, raising serious legal and ethical sourcing concerns.